MedTrace Logo

Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT01415518 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 581

Last updated 2019-07-09

Study results available
· View outcomes & findings →

Summary

Efficacy and tolerability study in severe chronic obstructive pulmonary disease (COPD) patients.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

Drug: Budesonide/formoterol (Symbicort Turbuhaler

budesonide/formoterol (Symbicort Turbuhaler 160/4.5µg/inhalation, 2 inhalations twice daily)

DRUG

Drug: ipratropium (AtroventTM)

ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily)

DRUG

theophylline SR

theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)

Sponsors & Collaborators

Principal Investigators

  • Samuel Chen · AstraZeneca Singapore Pte Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-01
Primary Completion
2012-12-01
Completion
2012-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01415518 on ClinicalTrials.gov